MAR 14, 2018 6:00 AM PDT

Targeting the Blood-Brain Barrier Transferrin Receptor for Delivery of Biologics for Alzheimer's Disease

Presented at: Neuroscience 2018
Speaker
  • Assistant Professor of Biopharmaceutical Sciences, Keck Graduate Institute School of Pharmacy
    Biography
      Dr. Sumbria received a Bachelor of Technology (B.Tech) in Pharmaceuticals & Fine Chemicals from the Institute of Chemical Technology in Mumbai, India in 2005, and a PhD in Pharmaceutical Sciences from the Texas Tech University Health Sciences Center (TTUHSC) in 2010. At TTUHSC, her research centered on the development of intracerebral microdialysis as an experimental tool to study changes in the blood-brain barrier (BBB) permeability in ischemic stroke. Dr. Sumbria completed her postdoctoral training at the Department of Medicine, blood-brain barrier laboratory at the University of California, Los Angeles and the Department of Neurology at the University of California, Irvine from 2011-2014. During her postdoctoral research at UCLA, Dr. Sumbria focused on the problem of the BBB bottleneck in CNS drug delivery. Particularly, her research focused on the use of receptor-mediated transcytosis for non-invasive delivery of biologics across the BBB, and studying their pharmacologic effects in different experimental models of CNS disorders. At UCI, the focus of her research was studying the role of cerebral microbleeds in cerebrovascular diseases like stroke. She joined the Keck Graduate Institute School of Pharmacy as an Assistant Professor in 2014 and is extensively involved in teaching and blood-brain barrier research. Her research is funded by the Alzheimer's Association, Joseph H. Stahlberg Foundation and NIH.

    Abstract

    98% of small molecules and 100% of large molecules do not cross the blood-brain barrier (BBB). Biologics, including therapeutic antibodies (e.g. anti-amyloid antibodies), have been at the forefront of Alzheimer’s disease (AD) research, however have had limited success so far. Biologics are large molecules with limited permeability across the BBB, and in the absence of a BBB-targeting approach to deliver these biologics to the brain, the true potential of the biologic cannot be determined. One approach to deliver a biologic, including anti-amyloid antibodies, decoy receptors and neurotrophins, for AD is to engineer bispecific fusion proteins, such that one domain of the fusion protein is the therapeutic biologic of interest, and the other domain acts as a molecular Trojan horse to ferry the biologic into the brain. This talk will focus on some of our work involving the targeting of the BBB transferrin receptor to deliver biologics (e.g. anti-amyloid antibody and biologic TNF-a inhibitor) in mouse models of AD.


    Show Resources
    You May Also Like
    MAY 11, 2021 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    MAY 11, 2021 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
    DEC 02, 2020 8:00 AM PST
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    MAR 16, 2021 10:00 AM PDT
    C.E. CREDITS
    MAR 16, 2021 10:00 AM PDT
    Date: March 16, 2021 Time: 10:00am (PST) Scientific progress and breakthroughs today are often too expensive for most institutions to acquire. Each year, the National Institutes of Health (N...
    APR 01, 2021 8:00 AM PDT
    C.E. CREDITS
    APR 01, 2021 8:00 AM PDT
    Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
    MAR 14, 2018 6:00 AM PDT

    Targeting the Blood-Brain Barrier Transferrin Receptor for Delivery of Biologics for Alzheimer's Disease

    Presented at: Neuroscience 2018

    Specialty

    Immunology

    Cancer Research

    Cancer Diagnostics

    Dna Sequencing

    Biomarkers

    Health

    Assay Development

    Clinical Research

    Laboratory Testing

    Protein

    Brain

    Cell Culture

    Gene Therapy

    Research And Development

    Pcr/rt-Pcr/real-Time Pcr

    Geography

    Asia50%

    Europe25%

    Africa25%

    Registration Source

    Website Visitors100%

    Job Title

    Student50%

    Educator/Faculty25%

    Medical Laboratory Technician25%

    Organization

    Academic Institution50%

    Hospital25%

    Manufacturer - Other25%


    Show Resources
    Loading Comments...
    Show Resources
    Attendees
    • See more